Introduction
According to the guidelines of many countries, patients with predicted low cardiovascular disease (CVD) risk do not require medication to prevent CVD. [1] [2] [3] [4] [5] [6] Nonetheless, preventive cardiovascular medication is often prescribed and used by patients with lower levels of predicted CVD risk than the actual guideline thresholds, because submit your manuscript | www.dovepress.com
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luymes et al recommendations for drug initiation have been revised after treatment has been started. 7, 8 Deprescribing these potentially inappropriate medications can reduce unnecessary adverse reactions in patients and undue medical costs. In an earlier study, we identified the barriers and enablers that patients and general practitioners (GPs) mention during consultations in which the deprescribing of preventive cardiovascular medication is discussed. 9 Patients expressed doubts about the appropriateness of their medication and seemed to rely on the information and expertise of their GP in determining whether deprescribing was justified. This finding was also observed in other studies. [10] [11] [12] Furthermore, a general dislike of medication and knowing that follow-up care was available and medication could be restarted are known to be enablers of deprescribing. 9, 13 Patients' expectations of the long-term medications they use play a role in their willingness to have their preventive medication deprescribed. Dohnhammar et al 14 reported that patients use medication to care for themselves above and beyond lifestyle changes alone and that they tend to overestimate the risk-lowering effects of preventive medication. Furthermore, patients and doctors balance risks and benefits of medication in a different way. For example, benefits in the short term are identified as more important to patients compared with doctors.
14 Patients' views on deprescribing their medication can thus be different than their physicians' views, but patient viewpoints could influence the implementation of preventive CVD management. Therefore, our objective was to identify various viewpoints and beliefs in patients with low CVD risk using preventive cardiovascular medication concerning preventive CVD management. Hence, we performed a Q-methodological study in patients with low CVD risk who had discussed deprescribing their preventive cardiovascular medication with their GP.
Methods
Q-methodology
To investigate the viewpoints of patients with low CVD risk concerning their preventive CVD management, a Q-methodological study was conducted. Q-methodology combines the strengths of both qualitative and quantitative methods, which enables the conversion of subjective perspectives into an objective outcome. 15 Although Q-methodology does not claim to identify viewpoints that are consistent within individuals across time, it is expected that viewpoints should show some degree of consistency over time. Hence, for the possible future implementation of a deprescribing policy, Q-methodology seems to be an appropriate way to investigate whether certain viewpoints are related to a preference for deprescription or for the continuation of preventive cardiovascular medication. 15 In contrast to qualitative analyses, Q-methodology focuses on groups instead of individuals, and therefore on the variety of viewpoints instead of on the viewpoint of the majority. It focuses on similarities and differences in a study population, resulting in various viewpoints or patterns of thought that specify a given population. The method consists of the following four steps, which we will further describe: 1) the determination of the concourse and generation of a Q-set, 2) the generation of a P-set (study population), 3) performing the Q-sorts, and 4) factor analysis and interpretation.
Q-set
The Q-set consisted of statements representing the concourse, the full range of contributions in the qualitative debate, on preventive CVD management. Statements were based on the literature, 10, 11, 13 expert opinion and data from our previous study concerning the barriers and enablers that patients mention during deprescribing consultations with their GPs. 9 Researchers (CHL, NLB, and RKEP) formulated 44 statements to cover the concourse. After testing the Q-set with four patients to determine the clarity of the statements and their sufficiency in displaying different viewpoints, a final Q-set of 43 statements was established. These were randomly numbered and printed on cards.
P-set
The study population was purposively sampled from the Evaluating Cessation of STatins and Antihypertensive Treatment In primary Care (ECSTATIC) trial (NTR3493). In the ECSTATIC trial (a randomized controlled trial that started in 2012, with follow-up ending in November 2015), we evaluated whether it is cost-effective and safe to deprescribe antihypertensive and lipid-lowering drugs in primary care patients for whom medication is not recommended according to the current Dutch guideline on Cardiovascular Risk Management (Box 1). Participants from the intervention practices were offered a consultation with their GP to discuss whether to deprescribe their preventive cardiovascular medication.
We sent written invitations to all patients from the intervention practices of the ECSTATIC trial (n=291) living in and around the cities of Leiden and Alphen aan den Rijn. Based on the preferred dates, we organized five sessions: three with patients who stopped their preventive cardiovascular medication 2 years ago and who still received no preventive cardiovascular medication (the deprescription 
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Q-sorts
The sorting board that patients used to rank statements followed the Q-convention of a "forced normal distribution" ( Figure S1 ).
Individual patients were given a pile of 43 statement cards and made piles containing statements with which they agreed, disagreed, or were neutral (no opinion or irrelevant). Next, each patient ordered the statements. On the extreme left, they placed the statements they disagreed with most. Next to those statements, they placed statements they disagreed with to a lesser extent, and so on. They did the same with the statements they agreed with most, except that these were placed on the right end of the sorting board. Finally, neutral statements were ordered and placed on the empty spots of the sorting board.
Factor analysis and interpretation
We analyzed the Q-sorts with PQMethod 2.35 software and used the varimax procedure to reveal the range of viewpoints that were favored by our study population. 15 An algorithm was used to calculate how high the correlation coefficient must be and how much the correlation coefficient of the factor must differ from the correlation coefficient of the other factors to state that a person loads on to that specific factor. The patients loading on a specific factor are the patients with the most representative Q-sorts for this factor. 16 Only the Q-sorts of patients loading on a specific factor were used for subsequent calculations. For each specific factor, an "ideal Q-sort" was created, showing how a hypothetical patient loading 100% on the factor would have ranked the statements. To interpret and name the factor, we used the Z-scores of the statements in these ideal Q-sorts, as well as the presented distinguishing and consensus statements of the factors. We reported statements distinguishing between any pair of factors with a P-value ,0.01 (distinguishing statements) and statements not distinguishing between any pair of factors with a P-value .0.01 (consensus statements).
After patients ranked their statements on the sorting board and their informed consent was audiotaped, we asked them to reflect on their rank ordering. Their reflections and the following group discussions were audiotaped and used for the further interpretation of the factors. Due to a technical problem in one of the sessions, we had to leave one group discussion from the desprescription group out of our analysis.
We identified the distribution of patients from the deprescription and continuation group across the factors. A chi-square test was used to examine the significance of this distribution.
To validate the factors that resulted from the Q-methodology, we made factor descriptions highlighting the important distinguishing characteristics of the different factors. This validation questionnaire was sent to the patients. We asked them how well each factor description fitted them, using a five-point Likert scale ranging from "totally not" to "very well". The study was approved by the Medical Ethics Committee of the Leiden University Medical Center.
Results
Of the 291 invited patients, 33 were willing to participate. There were no statistically significant differences between the respondents and nonrespondents with regard to age or gender. Two patients were excluded from the analysis of the Q-sorts
Box 1 ecsTATic trial
The ecsTATic trial evaluates whether it is cost-effective and safe to deprescribe antihypertensive and lipid-lowering drugs in primary care patients to whom medication is not recommended according to the current Dutch guideline on cardiovascular risk Management. Patients without cVD were included in the ecsTATic trial when having low cVD risk and using antihypertensive and/or lipid-lowering drugs. gPs in the intervention practices received a training providing information about this guideline and its differences with respect to the former guideline. in preparation of the deprescribing consultations, there were presented cases of fictional low CVD risk patients and they discussed these patients' suitability to have their medication deprescribed.
gPs participating in the trial sent a written invitation to their patients without cVD, using potentially inappropriate antihypertensive and/or lipid-lowering drugs. After obtaining the informed consent, the researchers determined eligibility on the basis of the patients' pretreatment 10-year risk of morbidity and mortality of cVD, using the scOre risk function as well as their (possible) additional risk increasing factors (positive family history for cVD, obesity, decreased kidney function, and sedentary lifestyle) (1). When, based on the combination of the risk score and additional risk increasing factors for cVD, medication was not recommended according to the current guideline cardiovascular risk Management, patients were considered eligible for inclusion and were advised to make an appointment for a deprescribing consultation with their gP. (incomplete Q-sort and language barrier). The characteristics of the patients who performed the Q-sort (n=31) and of those who participated in the group discussions (n=28) are shown in Table 1 . Table 2 shows the consensus and distinguishing statements in the Q-set. All patients had the idea that they could do something to reduce their CVD risk, even if CVD ran in their families (statement 5). Patients placed importance on a GP with good communication skills who explained their treatment options clearly (statement 12). They did not feel medications were unnatural (statement 6), and all patients regarded hypertension management as one of the GPs' job responsibilities (statement 7).
In addition, three distinguishable factors emerged from the Q-sorts (Table 2) , explaining 52% of the variance in our data. The patients from the description and continuation groups were unequally distributed across these factors (P=0.04).
Factor 1: controlling (n=13; seven from the deprescription group and six from the continuation group)
Patients loading on this factor placed great importance on the periodical monitoring of blood pressure and cholesterol levels by their GP, whether they were using medication or not (statement 19). During group discussions, these patients expressed dissatisfaction with their GP on this point: Hence, they felt that nobody should smoke (statement 34). In addition, they easily maintained a healthy lifestyle, and they never sought professional help to live (even) healthier (statements 23 and 36, respectively).
Factor 2: autonomous (n=8; seven from the deprescription group and one from the continuation group)
These patients would really appreciate living a long life without using medication, and they did not feel physically better when using medication (statements 33 and 21, respectively). Hence, they disagreed that using more and more medications comes along with growing old (statement 15). They disliked medication: Furthermore, they were interested in the way that the medication worked, and they knew exactly why they did 
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Understanding deprescribing of preventive cardiovascular medication far less when stopping it [the medication] was discussed.
[54-year-old man in the deprescription group]
Having a high blood pressure did not scare them, whereas having a low cardiovascular risk was a reason for them to deprescribe preventive cardiovascular medication, even if CVD ran in their families (statements 20 and 35, respectively). In contrast to the other factors, patients loading on this factor did not have that much confidence in the decisions their GP made for them (statement 32). These patients decided for themselves whether they would or would not use medication. Factor 3: afraid (n=8; two from the deprescription group and six from the continuation group)
Patients loading on this factor felt relieved when their blood pressure or cholesterol test result was in order and were afraid to develop a stroke or heart attack (statements 14 and 26). In contrast to the other factors, these patients did not hesitate to turn to professionals to help improve their lifestyle (statement 36). However, it was hard for them to change and maintain a healthy lifestyle (statement 23).
There is nothing as hard as changing your lifestyle.
[53-year-old man in the continuation group]
They were afraid of the negative effects of the longterm use of antihypertensive and lipid-lowering drugs (statement 10). Furthermore, they always read the information leaflet of their medications (statement 25). 
Notes:
a Well or very well. Bold data show the concordance between the factorloading according to analysis of the Q-sorts and the factor-fitting according to the patient. 
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Validation questionnaire
The validation questionnaire was sent to 31 patients. A total of 29 patients responded. Of these, 27 loaded onto one of three factors (Table 3) . In 74% (20/27) of the cases, patients self-selected the factor they loaded on, indicating that this factor fitted them "well" or very well. Seven patients reported that more than one factor description contained elements matching their ideas.
Discussion
With our Q-methodology study, we aimed 1) to identify the viewpoints of patients with low CVD risk concerning preventive CVD management and 2) to investigate whether certain viewpoints were related to a preference for either the deprescription or continuation of preventive cardiovascular medication. We found the following three viewpoints: 1) controlling, 2) autonomous, and 3) afraid viewpoints.
Patients who had their preventive cardiovascular medication deprescribed were differentially distributed across these viewpoints relative to patients who continued their medication. Most of the patients loading onto the autonomous viewpoint had their medication deprescribed, and most of the patients loading onto the afraid viewpoint had it continued. Several group discussion statements reinforced the findings of our Q-methodology, and in 74% of the cases, patients selfselected the factor they loaded on as fitting them well.
strengths and limitations
Using Q-methodology and postsort group discussions led to profound understanding of the factor arrays. The inclusion of patients who had deprescribed their medication and patients who had continued their medication ensured that different viewpoints were represented in our data. The participation grade of the study was fairly low, probably because of the fixed dates we offered for our sessions, combined with our working class population. However, as discussed by Watts and Stenner, 15 our sample size was considered sufficiently large for a Q-methodological study to reveal some of the main viewpoints that were favored by our specific study population. Moreover, our study population was similar to the nonrespondents in terms of age and gender. Because of their participation in the ECSTATIC trial, it is possible that our study population had more negative views toward preventive cardiovascular medication use than patients generally have. The outcomes might therefore not be generalizable in that respect. The goal of this Q-methodological study, however, was to identify different patterns of thought in our specific population. One of the strengths of this study is that the study population had previously discussed deprescribing with their GPs. We believe that this ensured that their views and opinions were well thought-out, resulting in balanced outcomes. Furthermore, it enabled us to link the patients who had deprescribed or continued their medication with the factors we found, revealing a more defined image of the viewpoints of patients loading on these factors. This information may be helpful for implementation purposes. In addition, by asking all patients how well each factor fitted them, we were able to show that our factor description indeed represented the viewpoints of the patients within the study population.
comparison with existing literature
Results from our Q-methodology overlap with the outcomes of several other studies. For example, similar observations had been made previously regarding the importance patients place on monitoring blood pressure and cholesterol 10, 13 (controlling and afraid), the role of stress as a cause of hypertension 17 (controlling), the search for aides in changing one's lifestyle to reduce the effects of modifiable factors that influence blood pressure and cholesterol, 10 and the fear of developing CVD 17 (afraid). It is known that a dislike of medication and a lack of confidence in its prescriber are enablers of deprescribing. 13, 18 These characteristics were shared by the patients loading on the autonomous viewpoint, and these patients were indeed more likely to have their medication deprescribed. However, the fear of side effects is also known as an enabler of deprescribing, 13 but patients loading onto the afraid viewpoint were more likely to continue their medication. This is likely because they feared CVD even more than the side effects, or because they were not able to change their lifestyle. 14 Morecroft et al 10 found that about half of the patients with hypertension believed that appropriate antihypertensive treatment involved leaving medical decisions to their GPs. Interestingly, all patients in our study population appreciated being involved in the general decision-making process. Considering the comparable age groups of both study populations, this may represent changing medical attitudes or cultural differences between patients in the UK and the Netherlands.
Practice implications
Knowing which views and thoughts patients have concerning preventive CVD management may be helpful for GPs when discussing this topic with a patient in daily practice. Furthermore, when planning to implement a deprescription strategy for inappropriate preventive cardiovascular medication, it Patient Preference and Adherence 2017:11 submit your manuscript | www.dovepress.com
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luymes et al seems appropriate to start implementation in patients who have an autonomous viewpoint because deprescribing is most likely to be successful in this group of patients. We believe that this approach to start implementation will not be very time-consuming because most GPs can clearly identify the patients who fit this profile.
Conclusion
The three well-discriminating viewpoints concerning preventive CVD management that emerged from our Q-methodological study (controlling, autonomous, and afraid) can be used for implementation and communication purposes in deprescribing. Table 4 shows some suggestions on how to detect patients with certain viewpoints and how to optimally communicate with them. 
